Irvine-based CG Oncology Inc., a biopharmaceutical company focused on treating bladder cancer, announced that it has completed enrollment for its Phase 3 PIVOT-006 trial.
CG Oncology enrolled more than 360 patients across 90 plus sites for the trial, which will compare its investigational immunotherapy versus surveillance in participants with intermediate-risk non-muscle invasive bladder cancer following bladder tumor removal.
“At CG Oncology, we remain steadfast in our mission to transform the treatment landscape for individuals living with bladder cancer,” CG Oncology Chief Medical Officer Vijay Kasturi said in a statement.
The company has two other ongoing studies, as well as a recently initiated expanded access program in North America for eligible patients in North America.
Shares in CG Oncology rose 1% to $27.75 and a $2 billion market cap (Nasdaq: CGON).
